Skip to main content

Table 1 Baseline characteristics in radium-223 treated patients according to symptom status

From: Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Characteristics Asymptomatic N = 135 Symptomatic N = 548
Age, median (range), years 73.0 (51.0–91.0) 72.0 (45.0–94.0)
Race, white 133 (99) 534 (97)
ECOG PS
 0 76 (56) 176 (32)
 1 52 (39) 293 (53)
 ≥2 7 (5) 79 (14)
Combined Gleason score at initial diagnosis
 2–4 2 (1) 13 (2)
 5–7 54 (40) 209 (38)
 8–10 67 (50) 277 (51)
 Missing 12 (9) 49 (9)
Alkaline phosphatase,a U/L
 Median (range) 127.0 (19.0–1349.0) 168.0 (22.0–4236.0)
Prostate specific antigen,b μg/L
 Median (range) 113.0 (0–3266.0) 154.6 (0–12,150.0)
Hemoglobin g/dL
 Median (range) 12.8 (8.7–15.8) 12.1 (8.4–18.0)
Time between initial diagnosis of prostate cancer and bone metastasis,c months
 Median (range) 30.2 (0–237.7) 13.6 (0–252.2)
Prior use of bone supportive agents
 Bisphosphonates 11 (8) 35 (6)
 Denosumab 4 (3) 10 (2)
Prior use of anticancer agents
 Docetaxel 70 (52) 339 (62)
 Abiraterone 34 (25) 190 (35)
 Enzalutamide 5 (4) 43 (8)
  1. Data are number of patients (%) unless stated otherwise
  2. aAsymptomatic, n = 133; symptomatic, n = 545
  3. bAsymptomatic, n = 134; symptomatic, n = 543
  4. cAsymptomatic, n = 87; symptomatic, n = 543
  5. ECOG PS Eastern Cooperative Oncology Group performance status